Proton Partners: First cancer patient receives proton beam therapy in UK

A new form of radiotherapy — high energy proton beam therapy — has been used for the first time in the UK.

The treatment was given to a pioneering unnamed prostate cancer patient at the new Rutherford Cancer Centre in Newport, South Wales. The centre is operated by Proton Partners International, a private company.

Within three years, the UK is expected to have at least six proton beam centres, two in the National Health Service and four run by Proton Partners for both private and NHS patients. Until now, British cancer patients have had to travel abroad to receive proton therapy at clinics in the US and elsewhere in Europe.

The beams deliver radiation in the form of protons — hydrogen nuclei — which can be targeted more accurately at tumours than the X-rays used to destroy cancer cells in conventional radiotherapy.

Proton Partners has estimated that about 9,000 of the 150,000 cancer patients who receive radiotherapy every year in the UK “would have a better outcome” if they were treated with proton beams, said Mike Moran, chief executive of the Cardiff-based company.

The company’s centres will have a capacity of about 500 patients a year, and each centre will cost about £35m to get fully operational. The proton generating equipment — made by a Belgian company, Ion Beam Applications — accounts for about half of the required investment.

A second centre will open by the end of this year in Bomarsund, Northumberland. It will be followed by others in Reading, Liverpool and London. The company’s long-term aim is to build eight centres in the UK, all branded as Rutherford Cancer Centres.

The NHS is also building higher capacity proton beam centres at the Christie Hospital in Manchester and University College London Hospital, where work is scheduled to begin by the end of 2018 and 2020, respectively.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Advanced Oncotherapy Plc

    More articles like this

    Hardman & Co

    Advanced Oncotherapy: Understanding the significance of 230MeV

    Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology, developed originally at the world-renowned CERN. The complex assembly of the first LIGHT accelerator in Daresbury

    Hardman & Co

    Advanced Oncotherapy: Major milestone achieved

    Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology, developed originally at the world-renowned CERN. The complex assembly of its first LIGHT accelerator in Daresbury

    Hardman & Co

    Advanced Oncotherapy: LIGHT – regulatory update

    Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. The company is in the process of completing the complex

    Hardman & Co

    Advanced Oncotherapy: On the home straight

    Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. Over the past two years, important technical milestones have significantly

    Hardman & Co

    Advanced Oncotherapy: Funded to completion

    Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. Over the past two years, important technical milestones have significantly

    Hardman & Co

    Advanced Oncotherapy: Leveraging the modularity of LIGHT

    Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. Over the past two years, important technical milestones have significantly

    Hardman & Co

    Advanced Oncotherapy funded through to clinical events

    AVO’s goal is to deliver an affordable and novel proton therapy (PT) system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. Over the past two years, the project has been significantly de-risked

    Hardman & Co

    Advanced Oncotherapy Rapidly changing to commercial execution

    Advanced Oncotherapy plc (LON:AVO) is the topic of discussion when Dr Martin Hall Analyst at Hardman & Co joins DirectorsTalk. Martin talks us through the interesting developments being made at the company, commercial deals, brings us up

    Hardman & Co

    Advanced Oncotherapy Confidence in LIGHT gaining momentum

    The Advanced Oncotherapy PLC (LON:AVO) goal is to deliver an affordable and novel proton beam therapy (PBT) system, based on state-of-the-art technology developed originally at the world-renowned CERN. In the past 18 months, the project has

    Hardman & Co

    Why is Advanced Oncotherapy well positioned for the future?

    Advanced Oncotherapy plc (LON:AVO) is the topic of conversation when Dr Martin Hall, Head of Life Sciences at Hardman & Co joins DirectorsTalk. Martin talks us through some interesting developments at the company, explains what has

    Hardman & Co

    Advanced Oncotherapy FLASH benefits from new US reimbursement

    Advanced Oncotherapy‘s (LON:ONC) goal is to deliver an affordable and novel proton beam therapy (PBT) system, based on state-of-the-art technology developed originally at the world-renowned CERN. In the past 18 months, the project has been de-risked